Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.
Advanced thymic carcinoma (TC) is a very aggressive disease. To date there are no established treatment options for the refractory and recurrent disease and only a few prospective trials have been conducted in patients with TC. Here we present a case of a relapsed TC patient, who, by using combination chemotherapy, showed a positive response to sorafenib with C-KIT exon 11 mutation.
Dişel
Umut
U
Baskent University, School of Medicine, Dept. of Medical Oncology, Adana, Turkey. doctorhope@gmail.com
Oztuzcu
Serdar
S
Beşen
Ali Ayberk
AA
Karadeniz
Cemile
C
Köse
Fatih
F
Sümbül
Ahmet Taner
AT
Sezer
Ahmet
A
Nursal
Gül Nihal
GN
Abalı
Hüseyin
H
Ozyılkan
Ozgür
O
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D005091:Exons; D005260:Female; D006801:Humans; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011725:Pyridines / Q000627:therapeutic use*; D017384:Sequence Deletion; D000077157:Sorafenib; D013953:Thymus Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D019009:Proto-Oncogene Proteins c-kit